Bain Capital, a Boston, MA-based global private investment firm, announced it has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation, an Osaka, Japan-based company developing drugs, in a carve-out transaction from Mitsubishi Chemical Group Corporation.
The investment is being led by Bain Capital’s Private Equity teams in Asia and North America together with the firm’s Life Sciences team and values the business at approximately 510 billion JPY (3.3 billion USD). The deal is expected to close in the third quarter of 2025 and is subject to customary closing conditions, regulatory clearance and shareholder approvals.
As an independent company, Tanabe Pharma will continue to build on its legacy of medical innovation while developing new opportunities for growth through business development, licensing activities, enhanced R&D productivity, commercialization and strategic acquisitions.
Founded in 1678, Tanabe Pharma focuses on several priority therapeutic areas, including immunology & inflammation, vaccines, central nervous system (CNS), diabetes and metabolic disease. It employs over 5,000 people globally.
Founded in 1984, Bain Capital is a private investment firms committed to creating impact for its investors, teams, businesses, and the communities. Its global platform invests across five focus areas: Private Equity, Growth & Venture, Capital Solutions, Credit & Capital Markets, and Real Assets.
FinSMEs
10/02/2025